Guillaume Cogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guillaume Cogan has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Brice
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Institut National de la Recherche Médicale-U1127, Centre National de la Recherche Scientifique-UMR7225, APHP, Paris, France
8 shared publications Suzanne Lesage
Sorbonne Université, Institut du Cerveau—Paris Brain Institute—ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Hôpital Pitié‐Salpêtrière Paris France
7 shared publications- Christelle Tesson
Sorbonne Université, Institut du Cerveau - Paris Brain Institute- ICM, Inserm, CNRS, APHP, University Hospital Pitié-Salpêtrière, Paris, France
6 shared publications - Cornelis Blauwendraat
Global Parkinson's Genetics Program, Chevy Chase, MD, USA; Coalition for Aligning Science (CAS), Chevy Chase, MD, USA
5 shared publications - Kimberley J. Billingsley
Center for Alzheimer’s and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
5 shared publications Eric LeGuern
Département de Génétique Médicale, UF de Neurogénétique Moléculaire et Cellulaire, Hôpital Pitié‐Salpêtrière AP‐HP Sorbonne Université Paris France
4 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by Wiley in Movement Disorders
Investigation of Parkinsonism‐Associated Genes in a Large Cohort of Individuals with Early‐Onset or Familial Predominant Parkinsonism
Background: A study of a large cohort, including early‐onset or familial patients with Parkinson's disease (PD), has deciphered the contribution of known PD genes. However, many other genes, thereafter labeled parkinsonism‐associated genes (PAG), are associated with other neurological conditions in which parkinsonism is sometimes reported. Objective: The aim was to evaluate the contribution of these genes in patients with predominant parkinsonism. Methods: We performed whole‐exome sequencing in a cohort of 1488 probands with early‐onset (here defined by an age at onset GBA1 , LRRK2 , PARK7 , PINK1 , PRKN , SNCA , VPS35 ). One hundred eighteen PAGs were selected for the analysis based on their assessment by experts in three different consortia (Genomics England PanelApp , PanelApp Australia, International Genetic Nomenclature in Movement Disorders Study Group). Pathogenic variants were extracted from these genes according to the criteria of the American College of Medical Genetics. Results: Eighty‐one probands (5.4%) carried a pathogenic variant of one PAG. Clinical review (available for 71/81 probands) revealed that the phenotype was compatible with the variant in 91.5% (65/71) of probands. Thirty‐seven genes were considered disease causing. Among them, six ( ATP13A2 , ATXN2 , FIG4 , GCH1 , PLA2G6 , PPP2R5D ) accounted for a large proportion of probands with a compatible phenotype (26/65, 40.0%). Conclusions: Our results indicate that PAGs would account for about 5% of patients with early‐onset or familial predominant parkinsonism not mutated for known PD genes, and that clinical evaluation is essential to establish causality. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 20 November 2026
- Published by Wiley in Movement Disorders
Open AccessInvestigation of Parkinsonism‐Associated Genes in a Large Cohort of Individuals with Early‐Onset or Familial Predominant Parkinsonism
Background: A study of a large cohort, including early‐onset or familial patients with Parkinson's disease (PD), has deciphered the contribution of known PD genes. However, many other genes, thereafter labeled parkinsonism‐associated genes (PAG), are associated with other neurological conditions in which parkinsonism is sometimes reported. Objective: The aim was to evaluate the contribution of these genes in patients with predominant parkinsonism. Methods: We performed whole‐exome sequencing in a cohort of 1488 probands with early‐onset (here defined by an age at onset GBA1 , LRRK2 , PARK7 , PINK1 , PRKN , SNCA , VPS35 ). One hundred eighteen PAGs were selected for the analysis based on their assessment by experts in three different consortia (Genomics England PanelApp , PanelApp Australia, International Genetic Nomenclature in Movement Disorders Study Group). Pathogenic variants were extracted from these genes according to the criteria of the American College of Medical Genetics. Results: Eighty‐one probands (5.4%) carried a pathogenic variant of one PAG. Clinical review (available for 71/81 probands) revealed that the phenotype was compatible with the variant in 91.5% (65/71) of probands. Thirty‐seven genes were considered disease causing. Among them, six ( ATP13A2 , ATXN2 , FIG4 , GCH1 , PLA2G6 , PPP2R5D ) accounted for a large proportion of probands with a compatible phenotype (26/65, 40.0%). Conclusions: Our results indicate that PAGs would account for about 5% of patients with early‐onset or familial predominant parkinsonism not mutated for known PD genes, and that clinical evaluation is essential to establish causality. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 25 September 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1) , 236
Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease
- 25 September 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1) , 236
Open AccessReply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease
- 10 February 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (7) , e52-e53
No role of intronic expansions in HSF1 for essential tremor in Europe
- 10 February 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (7) , e52-e53
No role of intronic expansions in HSF1 for essential tremor in Europe
- 20 November 2025
- Published by Elsevier in Current Opinion in Neurobiology
- Vol. 95, 103141
The genetics of autosomal recessive early-onset Parkinson's disease
- 20 November 2025
- Published by Elsevier in Current Opinion in Neurobiology
- Vol. 95, 103141
The genetics of autosomal recessive early-onset Parkinson's disease
- 15 November 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (7) , 2438-2448
The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probands
Genetic factors play an important role in frontotemporal lobar degeneration (FTLD), with about 20 genes reported to be involved. Although it is known that genetic diagnostic yield depends on age at onset, clinical subtype and family history, there are no precise indication criteria for a cost-effective and efficient strategy in a clinical setting. We report the molecular diagnostic experience in a French clinical laboratory in a large cohort of 2747 probands with sporadic or familial FTLD. We used a three-step genetic screening strategy. First, plasma progranulin was measured in all cases (n = 2747), followed by screening for GRN when plasma progranulin was below the threshold. If GRN screening was negative, the second step was to investigate the G4C2 repeat expansion in C9orf72 (n = 2675). In a third step, targeted sequencing of 14 FTLD genes was performed in 1279 individuals depending on age at onset and family history. The diagnostic yield of this strategy was 12.2% (n = 334). GRN (n = 73) and C9orf72 (n = 200) represented 81.7% of genetic diagnoses. The diagnostic yield of the panel sequencing was 4.8% (62/1279). Family history was the strongest factor related to genetic diagnosis, with four to five times more genetic diagnoses in cases with a family history of FTLD (32.1%) compared with sporadic cases (7.2%). However, the clinical presentation was not significantly associated with a genetic mutation, the behavioural variant of frontotemporal dementia (bvFTD) associated with amyotrophic lateral sclerosis (FTD/ALS), or not produced at a higher diagnostic yield (15.5% and 13.3%, respectively) than the primary progressive aphasia subgroup (9.9% for semantic variant and 8.8% for non-fluent variant) and others (8.3% and 4.2% for progressive supranuclear palsy and corticobasal syndrome, respectively). Interestingly, the genetic distribution varied greatly between clinical subtypes. FTD/ALS and bvFTD were mostly driven by C9orf72 (82.1% and 63.5%, respectively). In contrast, GRN was shown to be the dominant gene in nfvPPA (41.2%). C9orf72, MAPT, GRN and TBK1 equally contributed to svPPA (around 20% each). These results allow us to show the phenotype-genotype architecture of FTLD and to provide data to establish a cost-effective genetic diagnostic strategy in clinical settings for FTLD.
- 15 November 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (7) , 2438-2448
The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probands
Genetic factors play an important role in frontotemporal lobar degeneration (FTLD), with about 20 genes reported to be involved. Although it is known that genetic diagnostic yield depends on age at onset, clinical subtype and family history, there are no precise indication criteria for a cost-effective and efficient strategy in a clinical setting. We report the molecular diagnostic experience in a French clinical laboratory in a large cohort of 2747 probands with sporadic or familial FTLD. We used a three-step genetic screening strategy. First, plasma progranulin was measured in all cases (n = 2747), followed by screening for GRN when plasma progranulin was below the threshold. If GRN screening was negative, the second step was to investigate the G4C2 repeat expansion in C9orf72 (n = 2675). In a third step, targeted sequencing of 14 FTLD genes was performed in 1279 individuals depending on age at onset and family history. The diagnostic yield of this strategy was 12.2% (n = 334). GRN (n = 73) and C9orf72 (n = 200) represented 81.7% of genetic diagnoses. The diagnostic yield of the panel sequencing was 4.8% (62/1279). Family history was the strongest factor related to genetic diagnosis, with four to five times more genetic diagnoses in cases with a family history of FTLD (32.1%) compared with sporadic cases (7.2%). However, the clinical presentation was not significantly associated with a genetic mutation, the behavioural variant of frontotemporal dementia (bvFTD) associated with amyotrophic lateral sclerosis (FTD/ALS), or not produced at a higher diagnostic yield (15.5% and 13.3%, respectively) than the primary progressive aphasia subgroup (9.9% for semantic variant and 8.8% for non-fluent variant) and others (8.3% and 4.2% for progressive supranuclear palsy and corticobasal syndrome, respectively). Interestingly, the genetic distribution varied greatly between clinical subtypes. FTD/ALS and bvFTD were mostly driven by C9orf72 (82.1% and 63.5%, respectively). In contrast, GRN was shown to be the dominant gene in nfvPPA (41.2%). C9orf72, MAPT, GRN and TBK1 equally contributed to svPPA (around 20% each). These results allow us to show the phenotype-genotype architecture of FTLD and to provide data to establish a cost-effective genetic diagnostic strategy in clinical settings for FTLD.
- Open Access
- 23 June 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (9) , 2009-2011
Screening of Hidden Pathogenic Structural Variants in PRKN
- 23 June 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (9) , 2009-2011
Open AccessScreening of Hidden Pathogenic Structural Variants in PRKN
- Open Access
- 3 March 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (6) , 996-1008
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies
Genetic factors play a central role in neurodegenerative disorders. Over the past few decades, significant progress has been made in identifying the causative genes of numerous monogenic disorders, largely due to the widespread adoption of next‐generation sequencing (NGS) technologies in both research and clinical settings. However, many likely monogenic disorders still lack an accurate molecular diagnosis, primarily because conventional NGS methods are not effective at detecting structural variants and repeat expansions, both of which are crucial in many neurogenetic diseases. Recently, long‐read sequencing (LRS) and optical genome mapping technologies have emerged as powerful tools, offering the ability to capture more complex genetic variations. These technologies have already led to the discovery of novel genes responsible for well‐characterized neurodegenerative diseases (ND), enhancing the understanding of the biological underpinning of these conditions. Although currently LRS is mostly used in a research setting, we anticipate broader implementation of these methods in clinical laboratories in the near future. In this review, we explore the contributions of these technologies to ND research and highlight the remaining challenges for future advancements. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
- 3 March 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (6) , 996-1008
Open AccessExploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies
Genetic factors play a central role in neurodegenerative disorders. Over the past few decades, significant progress has been made in identifying the causative genes of numerous monogenic disorders, largely due to the widespread adoption of next‐generation sequencing (NGS) technologies in both research and clinical settings. However, many likely monogenic disorders still lack an accurate molecular diagnosis, primarily because conventional NGS methods are not effective at detecting structural variants and repeat expansions, both of which are crucial in many neurogenetic diseases. Recently, long‐read sequencing (LRS) and optical genome mapping technologies have emerged as powerful tools, offering the ability to capture more complex genetic variations. These technologies have already led to the discovery of novel genes responsible for well‐characterized neurodegenerative diseases (ND), enhancing the understanding of the biological underpinning of these conditions. Although currently LRS is mostly used in a research setting, we anticipate broader implementation of these methods in clinical laboratories in the near future. In this review, we explore the contributions of these technologies to ND research and highlight the remaining challenges for future advancements. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
- Open Access
- 13 February 2025
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 348 (G1) , 21-33
La maladie de Parkinson : de la génétique aux thérapies ciblées
La maladie de Parkinson (MP) est une maladie multifactorielle impliquant des facteurs génétiques et environnementaux. Cependant, l’âge de début, l’étendue des lésions et la rapidité de la progression peuvent varier de façon considérable, ce qui conduit à s’interroger sur l’unicité de la MP. L’identification de formes monogéniques, dont certaines semblent impliquer des mécanismes différents, renforce l’hypothèse de formes distinctes qui partagent la présence d’un syndrome parkinsonien. Alors que le gène SNCA fût le premier identifié dans les formes rares, les variants pathogènes dans les gènes GBA1 et LRRK2 représentent les causes génétiques ou facteurs de risque de MP les plus communs, et PRKN est le gène le plus souvent impliqué dans les formes autosomiques récessives de MP. Les patients présentant des variants SNCA, GBA1, LRRK2 ou PRKN diffèrent par certaines de leurs caractéristiques cliniques, anatomopathologiques et biochimiques. Ainsi, ces quatre gènes associés à la MP sont d’un intérêt tout particulier pour le développement de thérapeutiques spécifiques, d’autant que les approches thérapeutiques actuelles restent symptomatiques. Cependant, des essais cliniques fondés sur la nature du gène impliqué débutent. Dans cette revue, nous présentons les principales caractéristiques génétiques et physiopathologiques des gènes SNCA, GBA1, LRRK2 et PRKN avant de discuter des nouvelles approches thérapeutiques qui les ciblent spécifiquement.
- 13 February 2025
- Published by MathDoc/Centre Mersenne in Comptes Rendus. Biologies
- Vol. 348 (G1) , 21-33
Open AccessLa maladie de Parkinson : de la génétique aux thérapies ciblées
La maladie de Parkinson (MP) est une maladie multifactorielle impliquant des facteurs génétiques et environnementaux. Cependant, l’âge de début, l’étendue des lésions et la rapidité de la progression peuvent varier de façon considérable, ce qui conduit à s’interroger sur l’unicité de la MP. L’identification de formes monogéniques, dont certaines semblent impliquer des mécanismes différents, renforce l’hypothèse de formes distinctes qui partagent la présence d’un syndrome parkinsonien. Alors que le gène SNCA fût le premier identifié dans les formes rares, les variants pathogènes dans les gènes GBA1 et LRRK2 représentent les causes génétiques ou facteurs de risque de MP les plus communs, et PRKN est le gène le plus souvent impliqué dans les formes autosomiques récessives de MP. Les patients présentant des variants SNCA, GBA1, LRRK2 ou PRKN diffèrent par certaines de leurs caractéristiques cliniques, anatomopathologiques et biochimiques. Ainsi, ces quatre gènes associés à la MP sont d’un intérêt tout particulier pour le développement de thérapeutiques spécifiques, d’autant que les approches thérapeutiques actuelles restent symptomatiques. Cependant, des essais cliniques fondés sur la nature du gène impliqué débutent. Dans cette revue, nous présentons les principales caractéristiques génétiques et physiopathologiques des gènes SNCA, GBA1, LRRK2 et PRKN avant de discuter des nouvelles approches thérapeutiques qui les ciblent spécifiquement.
- Open Access
- 12 November 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (3) , 299-309
Use of Prenatal Exome Sequencing: Opinion Statement of the French Federation of Human Genetics Working Group
Objective: Prenatal whole exome sequencing (pES) is increasingly prescribed for fetuses with ultrasound anomalies. Starting from the local French prenatal medicine practice, healthcare system and legal landscape, we aimed to address the broad medical and ethical issues raised by the use of pES for women and couples as well as for prenatal care providers.Method: The French Federation of Human Genetics established a working group composed of clinicians and biologists from all over France to discuss pES challenges. A literature review was also performed.Results: We emphasize the importance of non‐directive information that helps couples make a decision that is consistent with their personal values and ideas. We address the difficulty of obtaining informed consent that respects the couple's autonomy, despite the complexity of the information and regardless of their level of education and cultural background. We address whether variants of uncertain significance and unsolicited results should be reported. We emphasize the need for national harmonization of access to pES and the need for multidisciplinary meetings in complex situations. We point out that the specific French context of healthcare financing and the French law have a major influence on medical care organization and support for couples. The outcome of the working group is the development of 12 proposals.Conclusion: This opinion statement, dedicated to prenatal care providers worldwide although linked to the French context, will provide food for thought and assist them in understanding the complexity and implications of pES.
- 12 November 2024
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (3) , 299-309
Open AccessUse of Prenatal Exome Sequencing: Opinion Statement of the French Federation of Human Genetics Working Group
Objective: Prenatal whole exome sequencing (pES) is increasingly prescribed for fetuses with ultrasound anomalies. Starting from the local French prenatal medicine practice, healthcare system and legal landscape, we aimed to address the broad medical and ethical issues raised by the use of pES for women and couples as well as for prenatal care providers.Method: The French Federation of Human Genetics established a working group composed of clinicians and biologists from all over France to discuss pES challenges. A literature review was also performed.Results: We emphasize the importance of non‐directive information that helps couples make a decision that is consistent with their personal values and ideas. We address the difficulty of obtaining informed consent that respects the couple's autonomy, despite the complexity of the information and regardless of their level of education and cultural background. We address whether variants of uncertain significance and unsolicited results should be reported. We emphasize the need for national harmonization of access to pES and the need for multidisciplinary meetings in complex situations. We point out that the specific French context of healthcare financing and the French law have a major influence on medical care organization and support for couples. The outcome of the working group is the development of 12 proposals.Conclusion: This opinion statement, dedicated to prenatal care providers worldwide although linked to the French context, will provide food for thought and assist them in understanding the complexity and implications of pES.
- Open Access
- 23 September 2024
- Published by Wiley in Movement Disorders
- Vol. 40 (1) , 174-175
Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease
- 23 September 2024
- Published by Wiley in Movement Disorders
- Vol. 40 (1) , 174-175
Open AccessConfirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease